<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perioperative blood management: Strategies to minimize transfusions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perioperative blood management: Strategies to minimize transfusions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Perioperative blood management: Strategies to minimize transfusions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Graetz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Nuttall, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aryeh Shander, MD, FCCM, FCCP, FASA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael F O'Connor, MD, FCCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Kleinman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4234253105"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic reviews the general approach to perioperative blood management, including strategies to avoid or minimize transfusion of blood components during surgical and other invasive procedures.</p><p>Separate topics discuss specific strategies for blood management during cardiac surgery with cardiopulmonary bypass (CPB). (See  <a class="medical medical_review" href="/d/html/94297.html" rel="external">"Blood management and anticoagulation for cardiopulmonary bypass"</a> and  <a class="medical medical_review" href="/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass"</a>.)</p><p>Indications, risks, and decision-making for intraoperative transfusion of specific blood components (eg, red blood cells [RBCs], fresh frozen plasma [FFP], platelets). Cryoprecipitate and administration of clotting factors (eg, <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a>, prothrombin complex concentrates, recombinant factor VIIa [rFVIIa]) are discussed separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors"</a>.) </p><p class="headingAnchor" id="H2301184984"><span class="h1">GOALS OF PATIENT BLOOD MANAGEMENT</span><span class="headingEndMark"> — </span>Patient blood management (PBM) is a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient’s own blood, while promoting patient safety and empowerment [<a href="#rid1">1-7</a>]. </p><p>Managing anemia and reducing the risk of anemia are intended to reduce transfusions of red blood cells (RBCs) and possibly other blood components, in turn reducing risks of anemia, transfusion reactions and other transfusion complications [<a href="#rid4">4,8,9</a>]. This patient-centered multimodality and multidisciplinary approach focuses on clinical outcomes rather than use of blood components [<a href="#rid6">6</a>]. Cost saving is a side benefit. </p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective study involving 25 hospital sites in Canada demonstrated significant reductions in blood component use over an 18-year period from 2002 to 2020 [<a href="#rid10">10</a>]. For example, the need for RBC transfusion was reduced from 25 to 0.4 percent in knee replacement surgery and from 60 to 27 percent in coronary artery bypass (CABG) surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another retrospective study in Australia estimated substantial cost savings after implementation of preoperative screening and management of anemia and suboptimal iron stores in patients undergoing elective colorectal surgery [<a href="#rid11">11</a>]. </p><p></p><p>Techniques and strategies for optimal PBM span the entire perioperative period from preoperative assessment until discharge from the hospital  (<a class="graphic graphic_table graphicRef120192" href="/d/graphic/120192.html" rel="external">table 1</a>) [<a href="#rid4">4,12</a>].</p><p>For major or complex surgical procedures with a known high risk of significant blood loss (&gt;500 to 1000 mL), advance discussions with the surgical team, a hemostasis expert, and/or the patient's primary clinician may identify opportunities to implement preoperative or intraoperative measures to avoid allogeneic transfusion, such as delay of an elective procedure to treat certain causes of anemia, preoperative autologous blood donation, intraoperative blood salvage, acute normovolemic hemodilution (ANH), or use of antifibrinolytic agents or other hemostatic products [<a href="#rid6">6,13</a>]. (See <a class="local">'Preoperative strategies'</a> below and <a class="local">'Intraoperative strategies'</a> below and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Use of clotting factors'</a>.)</p><p>Since the COVID-19 pandemic has resulted in many regional blood inventory shortages due to decreased donations, perioperative PBM is critically important to aid in balancing supply and demand for blood components [<a href="#rid4">4,14-17</a>]. </p><p>A comprehensive discussion of other strategies to minimize blood loss is presented separately. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Minimize blood loss'</a>.)</p><p class="headingAnchor" id="H2373181178"><span class="h1">PREOPERATIVE STRATEGIES</span><span class="headingEndMark"> — </span>The preanesthetic consultation provides an opportunity to assess and address risks for bleeding and to evaluate possible interventions to minimize the need for transfusions  (<a class="graphic graphic_table graphicRef120192" href="/d/graphic/120192.html" rel="external">table 1</a>) [<a href="#rid4">4,18-21</a>]. Certain disorders (eg, anemia), surgical procedures (eg, cardiac surgery, liver transplantation), and medications that affect hemostasis (anticoagulants and antiplatelet agents) are associated with increased potential for bleeding and transfusion.</p><p class="headingAnchor" id="H1196276668"><span class="h2">Elective surgical procedures</span><span class="headingEndMark"> — </span>It may be appropriate to postpone an elective procedure when there is a reversible cause of anemia or coagulopathy that can be corrected in a reasonable period of time  (<a class="graphic graphic_algorithm graphicRef120496" href="/d/graphic/120496.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2354604631"><span class="h3">Selective laboratory testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin or complete blood count</strong> – A baseline hemoglobin measurement (typically a component of a complete blood count [CBC]) is obtained in patients undergoing selected major surgery surgical procedures that have significant expected blood loss (procedures with &gt;10 percent chance of needing a transfusion or &gt;500 mL blood loss). Preoperative anemia due to a known underlying condition should be evaluated and appropriately managed before surgery unless the scheduled procedure is minor. (See <a class="local">'Treatment of anemia'</a> below.)</p><p></p><p class="bulletIndent1">Ideally, a baseline CBC is obtained approximately four weeks prior to scheduled major elective surgery. This allows adequate time for appropriate treatment of anemia, such as replacement of iron stores in individuals with iron deficiency [<a href="#rid22">22</a>]. In some cases, elective surgery may need to be delayed  (<a class="graphic graphic_algorithm graphicRef120496" href="/d/graphic/120496.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Hospital-wide oversight programs/patient blood management'</a>.)</p><p></p><p class="bulletIndent1">By contrast, a CBC or hemoglobin measurement is not necessary for patients undergoing minor surgery unless the history suggests anemia. (See  <a class="medical medical_review" href="/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient", section on 'Complete blood count'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening tests for bleeding disorders </strong>– For patients with a personal history, family history, or physical examination suggesting the presence of a bleeding disorder, appropriate screening tests should be obtained. These often include, but are not limited to, a platelet count and screening tests of coagulation (prothrombin time [PT] with international normalized ratio [INR] and activated partial thromboplastin time [aPTT]) [<a href="#rid18">18,23,24</a>]. In some cases, liver function tests or tests of kidney function (creatinine) may also be obtained. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p></p><p class="bulletIndent1">If indicated, such screening should be done early enough to allow time for diagnosis and treatment of causes of hemostatic abnormalities. A hematology consultation is typically necessary. In selected cases (eg, patients with significant prior bleeding episodes or recent decrease in hemoglobin level or need for transfusion), it is appropriate to obtain a consultation even if screening tests are normal. However, we do not obtain screening tests of coagulation unless a bleeding disorder is suspected, in accord with the recommendations of the American Society of Anesthesiologists [<a href="#rid25">25</a>], the British Committee for Standards in Hematology [<a href="#rid26">26</a>], and the European Society of Anaesthesia [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/1315.html" rel="external">"Preoperative assessment of bleeding risk", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1">Routine screening for thrombocytopenia is not indicated in patients without a suspected bleeding disorder, as isolated thrombocytopenia is rare and usually identified before preoperative testing [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/1315.html" rel="external">"Preoperative assessment of bleeding risk", section on 'Avoid routine testing in unselected individuals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for individuals receiving anticoagulants</strong> – Individuals receiving anticoagulants typically have recent laboratory testing available that should be reviewed (eg, PT/INR for those on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, creatinine for those on a <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> or a direct factor Xa inhibitor). This information may factor into decisions regarding the preoperative timing of anticoagulant discontinuation. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typing and crossmatching tests </strong>– Typing and crossmatching tests to ensure availability of appropriate blood components are necessary before procedures with large expected blood loss; the blood bank or transfusion medicine service should be notified of the approximate number of units that are likely to be required based on known blood loss associated with the specific procedure as well as the potential for greater than average blood loss that may occur or may be poorly tolerated in certain patients (eg, those with comorbidities).</p><p></p><p class="headingAnchor" id="H2666502152"><span class="h3">Treatment of anemia</span><span class="headingEndMark"> — </span>Anemia is a highly prevalent risk factor for morbidity and mortality in surgical patients and is independently associated with increased risk of transfusion [<a href="#rid1">1,20,21,29-33</a>]. Chronic anemia can be a marker for other comorbidities in addition to being a direct cause of morbidity and mortality [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Impact of anemia on morbidity and mortality'</a>.)</p><p>Depending on the cause and degree of anemia, the urgency of the procedure, and the expected amount of blood loss and other risk factors, surgery may be postponed to diagnose the cause of anemia and provide treatment when feasible, in order to minimize the risk of perioperative transfusion of red blood cells (RBCs)  (<a class="graphic graphic_algorithm graphicRef120496" href="/d/graphic/120496.html" rel="external">algorithm 1</a>) [<a href="#rid4">4,19-21,29-31,35-39</a>]. </p><p>While many patients with preoperative anemia have iron deficiency or anemia of chronic disease/anemia of inflammation, other causes of anemia include folate and <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> deficiencies [<a href="#rid31">31</a>]. For patients who have unknown or complex causes of anemia, input is sought from a consultant with expertise in anemia management. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'ESAs'</a> and  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia"</a> and  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.) </p><p class="headingAnchor" id="H2826390810"><span class="h4">Iron deficiency anemia</span><span class="headingEndMark"> — </span>Iron deficiency anemia is a surprisingly common condition across various surgical and other patient populations [<a href="#rid1">1,4,20,30,31,33,40-43</a>]. Even among patients whose anemia is attributed to other causes (eg, chronic kidney disease or inflammation), some degree of iron deficiency may be present. Individuals with iron deficiency should be treated with iron rather than transfusion, unless the anemia is extremely severe and there is risk of organ ischemia, as discussed separately. If iron is administered, sufficient time should be allowed for effective treatment of anemia before surgery (typically two to four weeks for partial correction and six to eight weeks for full correction). In individuals with unexplained iron deficiency, determination of the underlying cause is an essential part of management. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p>Oral iron replacement can be initiated in an iron-deficient patient if at least four to six weeks of time is available before planned surgery. Intravenous (IV) iron is an option if there is less than four to six weeks until semi-elective surgery, and for patients who cannot tolerate oral iron or do not have a response (eg, due to poor absorption) [<a href="#rid20">20,21,30,33,35,39,44-46</a>]. In this setting, IV iron can replenish body iron stores more rapidly and effectively than oral iron therapy; however, time is still required for the iron to be incorporated into developing RBCs and for the hemoglobin level to increase, and available trials have not been adequately powered to determine whether rates of transfusion are lower [<a href="#rid31">31,33,43,46-49</a>]. Details regarding decision-making and treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Perioperative'</a>.) </p><p class="headingAnchor" id="H732899621"><span class="h4">Use of erythropoietin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– Erythropoietin (EPO) can increase RBC production and increase the hemoglobin level, potentially reducing patients' exposures to allogeneic transfusion [<a href="#rid31">31</a>]. Administration of EPO typically should include supplemental iron to avoid functional iron deficiency that may occur in face of increased erythropoiesis.</p><p></p><p class="bulletIndent1">EPO for treatment of anemia can be used in the following settings for scheduled surgical procedures [<a href="#rid1">1</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with anemia of chronic disease/anemia of inflammation undergoing a scheduled major noncardiac surgical procedure with expected blood loss &gt;500 mL if hemoglobin is &lt;12 g/dL [<a href="#rid50">50</a>]. Clinical judgment is used for patients with hemoglobin levels between 12 and 13 g/dL. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with anemia of chronic disease/anemia of inflammation undergoing cardiac surgery if hemoglobin &lt;13 g/dL. Our approach is consistent with guidelines from the European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Cardiothoracic Anaesthesiology (EACTA), and the Society of Cardiovascular Anesthesiologists, which recommend consideration of preoperative EPO administration with concomitant IV iron for anemic cardiac surgical patients, even if iron deficiency or iron deficiency anemia is absent [<a href="#rid33">33,38,51</a>]. (See  <a class="medical medical_review" href="/d/html/94291.html" rel="external">"Preoperative evaluation for anesthesia for cardiac surgery", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with anemia of chronic kidney disease (CKD), especially those receiving dialysis. (See <a class="local">'Anemia associated with chronic kidney disease'</a> below and  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Erythropoiesis-stimulating agents (ESAs)'</a> and  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Erythropoiesis-stimulating agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients for whom blood transfusion is not an option, as described separately. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Erythropoiesis-stimulating agents (ESAs/EPO)'</a>.)</p><p></p><p class="bulletIndent1">Our general approach does not take the place of the judgment of the surgeon, anesthesiologist, internist, nephrologist, or hematologist regarding likelihood of avoiding transfusion and the risks and benefits of EPO administration for an individual patient. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – We typically begin EPO therapy three weeks before an elective procedure and provide three injections of 40,000 units or 300 to 600 units/kg of <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> once weekly, together with supplemental iron to avoid functional iron deficiency. If less than three weeks is available, we still administer EPO prior to the surgical procedure as it may still provide benefit. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential adverse effects of EPO include venous thromboembolism, hypertension, and possible adverse outcomes in patients with cancer being treated with curative intent, and it is reasonable to avoid EPO in individuals with severe uncontrolled hypertension or those with cancer receiving chemotherapy with curative intent. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Erythropoiesis-stimulating agents (ESAs/EPO)'</a> and  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"</a>.):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – There is significant heterogeneity among published studies with respect to dosing and timing of preoperative EPO administration, the presence, cause, and severity of preoperative anemia and/or iron deficiency, whether iron therapy was concomitantly administered, and the types of surgical procedures studied [<a href="#rid31">31</a>]. Data regarding benefits and risks of preoperative EPO administration are summarized as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2020 meta-analysis of randomized trials that included 1880 anemic patients (hemoglobin &lt;13 g/dL for males or &lt;12 g/dL for nonpregnant females) undergoing noncardiac surgery (primarily orthopedic, gastrointestinal, and gynecological surgery) compared administration of preoperative EPO plus iron therapy with placebo or standard of care (with or without iron) [<a href="#rid52">52</a>]. Preoperative EPO plus iron reduced the need for RBC transfusion (risk ratio [RR] 0.55, 95% CI 0.38-0.80).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2019 meta-analysis of randomized trials comparing preoperative administration of EPO versus placebo (32 trials; 4750 patients, mostly orthopedic and cardiac surgery) found reduced blood transfusions in the EPO groups [<a href="#rid53">53</a>]. Decreased blood transfusions were seen in the entire population (RR 0.59, 95% CI 0.47-0.73; 28 trials), as well as the subgroups undergoing cardiac surgery (RR 0.55, 95% CI 0.47-0.73; nine trials) and major orthopedic surgery (RR 0.36, 95% CI 0.28-0.46; five trials). In addition, the EPO group had increased hemoglobin levels. There was no increase in the incidence of thromboembolic events with EPO.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another 2019 randomized trial in elective cardiac surgical patients with preoperative anemia or isolated iron deficiency noted reduced RBC transfusions from a median of one to zero units in those who received preoperative subcutaneous EPO administered together with IV iron, subcutaneous <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a>, and oral <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> on the day before surgery, compared with those receiving placebo drugs (odds ratio [OR] 0.70, 95% CI 0.50-0.98) [<a href="#rid54">54</a>]. Post-hoc analysis of this trial confirmed that such "quadruple anemia treatment" significantly increased reticulocyte count on postoperative days 1,3, and 5 in patients with or without preoperative iron deficiency [<a href="#rid55">55</a>]. However, it is unknown whether administration of IV iron without EPO would have been equally effective in patients with iron deficiency, or whether giving vitamin B12 and folate conferred any additional benefit. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2018 randomized trial in orthopedic surgical patients with hemoglobin 10 to 13 g/dL before hip or knee arthroplasty reported greater iron stores and improved erythropoiesis after treatment with weekly EPO plus concomitant administration of IV iron for three weeks before surgery, compared with treatment with EPO plus oral iron for the same period [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H3546930489"><span class="h4">Anemia associated with chronic kidney disease</span><span class="headingEndMark"> — </span>Management of patients with chronic kidney disease (CKD; with or without hemodialysis) may include iron and/or EPO. (See  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Treatment'</a>.) </p><p>Details of therapy should be discussed with the patient's primary nephrologist. In particular, we try to avoid transfusion when possible in any patient on a transplant waiting list, as transfusion-induced allosensitization to HLA antigens may affect transplant outcomes. However, transfusion should not be withheld from an individual awaiting a kidney transplant if indicated to treat more severe symptomatic anemia. </p><p class="headingAnchor" id="H4275723717"><span class="h3">Preoperative autologous blood donation</span><span class="headingEndMark"> — </span>Preoperative autologous donation has been declining and is only rarely used due to high wastage of the autologous units, increased risk of anemia, increased risk of needing allogeneic transfusion, expense, and inconvenience [<a href="#rid56">56</a>]. Occasionally, preoperative autologous donation is used upon request as a blood conservation option in individuals in relatively good health who are not anemic prior to undergoing surgical procedures with significant expected blood loss (≥500 to 1000 mL) [<a href="#rid56">56</a>]. Recombinant human EPO may be used as an adjunct [<a href="#rid19">19</a>]. Further discussion is available in a separate topic. (See  <a class="medical medical_review" href="/d/html/7930.html" rel="external">"Surgical blood conservation: Preoperative autologous blood donation"</a>.)</p><p class="headingAnchor" id="H74868085"><span class="h3">Management of thrombocytopenia or platelet dysfunction</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – For individuals with known thrombocytopenia, discussions with the surgeon and consulting hematologist or the patient's primary clinician should focus on determining a safe platelet count for the proposed procedure and appropriate interventions to raise the platelet count to a safe level if needed. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Preparation for an invasive procedure'</a>.)</p><p></p><p class="bulletIndent1">For patients who are found to have a low platelet count, causes of thrombocytopenia are evaluated prior to elective surgery. Depending on the type and urgency of the surgical procedure and the cause and degree of thrombocytopenia, surgery may be postponed and/or therapy may be given to increase the platelet count before the procedure. Suggested platelet count thresholds for various common invasive procedures are discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Preparation for an invasive procedure'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune thrombocytopenia (ITP)</strong> – For some elective procedures in patients with ITP, properly-timed glucocorticoids and/or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) can be used to raise the platelet count before surgery. The table shows the expected time to first response for various ITP treatments  (<a class="graphic graphic_table graphicRef87698" href="/d/graphic/87698.html" rel="external">table 2</a>). If time is not an issue, we generally use the agent that has previously been effective for the individual patient. (See  <a class="medical medical_review" href="/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Surgery or delivery'</a>.) </p><p></p><p class="bulletIndent2">Data are limited for the use of other approaches such as administration of a thrombopoietin receptor agonist (TPO-RA) prior to surgery in individuals with ITP [<a href="#rid57">57</a>]. Indications and the time to expected response are discussed separately. (See  <a class="medical medical_review" href="/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors", section on 'Use of TPO receptor agonists'</a> and  <a class="medical medical_review" href="/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – In contrast with ITP, there is evidence that individuals with liver disease who have significant thrombocytopenia and are undergoing an elective procedure with a high bleeding risk can be treated with a properly-timed TPO-RA prior to the procedure. Details are available in a separate topic. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet dysfunction</strong> – The functional status of platelets is also important in decisions regarding platelet transfusion before or during surgery. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors"</a> and  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Platelets'</a>.) </p><p></p><p class="bulletIndent1">Some studies suggest that platelet function tests better predict surgical bleeding than the platelet count [<a href="#rid58">58,59</a>]. However, there is insufficient evidence to incorporate these tests as part of routine preoperative assessment.</p><p></p><p class="bulletIndent1">Topics addressing further management of patients with specific disorders of platelet function include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uremia</strong> – Many, but not all uremic patients have an increased risk of bleeding; some have an increased risk of thrombosis. (See  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Treatment of bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – Patients with severe liver disease may have platelet dysfunction in addition to thrombocytopenia. Thrombosis risk may also be increased. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inherited disorders of platelet function</strong> – (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p></p><p class="headingAnchor" id="H2543769337"><span class="h3">Management of medications affecting hemostasis</span><span class="headingEndMark"> — </span>Some patients undergoing surgery are taking medications intended to reduce the risk of thrombosis (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or another anticoagulant, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or a P2Y<sub>12</sub> inhibitor such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>). In some cases, medications taken for other indications may alter hemostasis (eg, nonsteroidal antiinflammatory drugs [NSAIDs], herbal medications).</p><p>Appropriate perioperative management of a patient taking a specific medication depends on the indication for which the agent was prescribed, the underlying thrombotic risk, the planned surgical procedure, and other factors that affect bleeding risk [<a href="#rid1">1</a>]. Discontinuation of antithrombotic medications is often appropriate, with the details of timing typically determined using institutional or other guidelines as well as consultation with the surgeon and the prescribing clinician. These management decisions are discussed in separate topics:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiplatelet agents (</strong><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a><strong>, other antiplatelet agents, nonsteroidal antiinflammatory agents)</strong> – (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Medications affecting hemostasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulants</strong> – (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herbal medications that affect hemostasis (eg, ginkgo biloba, garlic)</strong> – (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Herbal medications'</a>.)</p><p></p><p class="headingAnchor" id="H1535228623"><span class="h3">Management of specific hemostatic disorders</span><span class="headingEndMark"> — </span>Perioperative management of patients with inherited or acquired disorders that affect hemostasis is discussed in UpToDate topics for the specific disease. The most common examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease </strong>– Patients with liver disease may have abnormalities in routine laboratory tests of coagulation, especially when liver synthetic function is significantly impaired and portal pressures are increased. These include prolongation of the PT, INR, and aPTT, as well as mild thrombocytopenia and elevated D-dimer. Both quantitative and qualitative platelet disorders are a consequence of chronic and acute liver damage. Individuals with hepatic insufficiency also have abnormalities that may increase the risk of thrombosis. Consequently, laboratory abnormalities are poor predictors of bleeding risk. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Laboratory abnormalities'</a>.)</p><p></p><p class="bulletIndent1">Perioperative management of hemostatic abnormalities in patients with liver disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other acquired disorders of hemostasis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin K</strong><strong> deficiency </strong>– <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a> deficiency may develop in individuals with reduced oral intake or decreased absorption due to conditions such as cystic fibrosis, biliary atresia, sclerosing cholangitis, cholestasis, or intestinal diseases with malabsorption. Significant vitamin K deficiency will prolong the PT. Vitamin K deficiency can be treated with vitamin K, which may take one or more days to be effective, or with an unactivated prothrombin complex concentrate (PCC) if needed for emergency surgery with a significant bleeding risk. (See  <a class="medical medical_review" href="/d/html/2624.html" rel="external">"Overview of vitamin K", section on 'Vitamin K deficiency'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disseminated intravascular coagulation</strong> – (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired coagulation factor inhibitors</strong> (autoantibodies against factors II, V, VII, VIII [acquired hemophilia A], IX, XI, or XIII) – (See  <a class="medical medical_review" href="/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited conditions affecting hemostasis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemophilia</strong> – (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Elective surgery'</a> and  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Urgent/emergency surgery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other heritable coagulation factor deficiencies</strong> (eg, factor XIII, XI, X, VII, V, II [prothrombin], fibrinogen) – (See  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Invasive procedure/surgery'</a> and  <a class="medical medical_review" href="/d/html/1321.html" rel="external">"Disorders of fibrinogen", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Von Willebrand disease (VWD) </strong>– (See  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'Minor bleeding and minor surgery'</a> and  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery", section on 'Overview of approach'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other disorders that cause platelet dysfunction or thrombocytopenia</strong> – (See  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'Categories of causes'</a>.)</p><p></p><p class="headingAnchor" id="H2795320410"><span class="h3">Consents and advanced directives</span><span class="headingEndMark"> — </span>Patient preferences and acceptance or declining various blood components and/or blood conservation modalities should be discussed in the preoperative period. Related consents and advanced directives should be obtained and documented in the preoperative period to ensure that acceptable options for optimal care are provided [<a href="#rid1">1,60-62</a>].</p><p>Certain patients may decline transfusions, or appropriate blood products may be limited or unavailable for other reasons (eg, previously transfused patients with multiple alloantibodies or incompatible cross-matching for other reasons, wounded soldiers on the battlefield, surgical procedure performed in areas of limited blood supply). These situations pose additional challenges for treatment of severe anemia, and for cases in which significant blood loss is likely [<a href="#rid61">61-63</a>]. Specific arrangements regarding acceptable alternatives should be made in advance to allow provision of the most effective care while respecting the patient's preferences, values, and their right of self-determination [<a href="#rid61">61-64</a>]. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Be clear about the patient's wishes regarding consent'</a>.)</p><p>There may be substantial variability in acceptance of various components and factors, necessitating discussion of specific transfusion decisions on an individual basis before invasive interventions [<a href="#rid61">61,62,65,66</a>]. As an example, acute normovolemic hemodilution (ANH) may be a good option for Jehovah Witnesses who consent to ANH if the blood is maintained in a contiguous circuit with the circulation. (See <a class="local">'Acute normovolemic hemodilution'</a> below.) </p><p>Investigational hemoglobin-based oxygen carriers or other oxygen delivery vehicles (eg, perfluorocarbon) have been employed in rare cases when blood components were not an option [<a href="#rid67">67</a>]. Strategies to optimize preoperative red cell mass and minimize blood loss in patients who decline blood transfusions are presented separately. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion"</a> and  <a class="medical medical_review" href="/d/html/7923.html" rel="external">"Oxygen carriers as alternatives to red blood cell transfusion"</a>.)</p><p class="headingAnchor" id="H2111932693"><span class="h2">Urgent and emergency surgical procedures</span><span class="headingEndMark"> — </span>For urgent or emergency surgery, it may be impossible to address all factors adversely affecting baseline hemoglobin, coagulation, bleeding, and the potential need for transfusion of blood products [<a href="#rid1">1</a>]. For example, it is not possible to correct iron deficiency anemia before emergency surgery [<a href="#rid68">68</a>], because iron must be incorporated into developing blood cells. Specific issues may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemorrhage</strong> – When blood loss is rapid or extensive, or when the hemoglobin level drops below a defined threshold, RBC transfusion may be necessary in the preoperative period. Perioperative indications for transfusion of RBCs are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Red blood cells'</a> and  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Thresholds for specific patient populations'</a>.)</p><p></p><p class="bulletIndent1">In patients with major bleeding and coagulopathy (eg, due to trauma), goal-directed replacement of blood components and coagulation factors is recommended [<a href="#rid69">69,70</a>]. For those requiring massive transfusion of blood components (RBCs, plasma products, platelets), administration of crystalloid solutions should be monitored and minimized as much as possible throughout the perioperative period to avoid dilutional coagulopathy [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/d/html/94581.html" rel="external">"Anesthesia for adult trauma patients", section on 'Blood and fluid administration'</a> and  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a> and  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'VHA-based dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulants</strong> – Anticoagulant reversal may be necessary before an emergency procedure [<a href="#rid73">73,74</a>]. However, not all individuals and surgical settings require reversal, especially if thrombotic risk from an underlying condition is high and bleeding risk of the surgery is low. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1">Strategies for anticoagulant reversal for an urgent or emergency procedure are discussed in detail in separate topic reviews:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Warfarin</strong><strong> or other </strong><strong>vitamin K</strong><strong> antagonist</strong>  (<a class="graphic graphic_table graphicRef79151" href="/d/graphic/79151.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef89478" href="/d/graphic/89478.html" rel="external">table 4</a>) – (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a>.)</p><p></p><p class="bulletIndent2">A 4-component PCC product is the preferred therapy for a patient receiving a <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonist who requires immediate reversal of anticoagulation for urgent surgery, including in the setting of intracranial hemorrhage [<a href="#rid75">75</a>]. Compared with plasma in this setting, PCC has been associated with a more rapid correction of the INR and reversal of anticoagulation [<a href="#rid75">75</a>]. Concomitant vitamin K also needs to be administered because the half-life of PCCs is short. </p><p></p><p class="bulletIndent2">Details and supporting data are available in separate topics: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Intracerebral hemorrhage – (See  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.) </p><p class="bulletIndent3"><span class="glyph">-</span>Prosthetic heart valve – (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p class="bulletIndent3"><span class="glyph">-</span>All other patients – (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Direct oral anticoagulants </strong>(DOACs; direct oral thrombin inhibitor <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> and direct factor Xa inhibitors)  (<a class="graphic graphic_table graphicRef96230" href="/d/graphic/96230.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef112299" href="/d/graphic/112299.html" rel="external">table 6</a>) – (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heparin</strong> – (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Reversal'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fondaparinux</strong> – (See  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects", section on 'Management and prevention of bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Platelet transfusions may be required for severe thrombocytopenia in patients who require emergency major surgery when there is insufficient time to raise the platelet count by treating the underlying condition responsible for thrombocytopenia (eg, use of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> in an individual with ITP). </p><p></p><p class="bulletIndent1">In such cases, indication for platelet transfusion includes a count that is &lt;50,000/microL, although a higher transfusion threshold may be used in selected cases (eg, &lt;100,000/microL for neurosurgical or ocular procedures). Platelet transfusion is usual<strong>ly not</strong> necessary for minor invasive procedures such as placement of a central venous catheter unless the platelet count is &lt;20,000/microL [<a href="#rid76">76-78</a>]. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Preparation for an invasive procedure'</a>.)</p><p></p><p class="bulletIndent1">Perioperative management of patients receiving antiplatelet therapy is discussed separately [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Medications affecting hemostasis'</a>.)</p><p></p><p class="headingAnchor" id="H1888380099"><span class="h1">INTRAOPERATIVE STRATEGIES</span></p><p class="headingAnchor" id="H1467389423"><span class="h2">Transfusion thresholds</span><span class="headingEndMark"> — </span>For most patients who do not have significant intraoperative blood loss (blood loss &lt;500 mL), we use a restrictive transfusion threshold (typically defined as transfusion restricted to those with hemoglobin &lt;7 g/dL, or in some cases, &lt;8 g/dL) [<a href="#rid1">1</a>]. Details are discussed separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors", section on 'Red blood cells'</a> and  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p>To replace lost blood volume, transfusions should only be used if the hemoglobin threshold is reached and/or the patient exhibits clinical signs of acute anemia. However, significant bleeding (&gt;500 mL) or bleeding at a rate such that the hemoglobin level does not accurately reflect the patient's clinical status and cannot be immediately stopped may require transfusions of red blood cells (RBCs) in addition to fluid therapy. (See  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Choosing fluid: Crystalloid, colloid, or blood'</a>.)</p><p class="headingAnchor" id="H10487212"><span class="h2">Fluid management</span><span class="headingEndMark"> — </span>Until the hemoglobin drops below the transfusion threshold (see <a class="local">'Transfusion thresholds'</a> above), we typically administer fluid as necessary to maintain normovolemia, using either a balanced electrolyte crystalloid solution administered on a 1.5:1 basis, or a colloid solution administered on a 1:1 basis with an equal volume of colloid to volume of lost blood.</p><p>Administration of standardized large volumes of crystalloid solution (eg, a fixed volume or traditional liberal approach to fluid therapy) should be avoided since this is associated with dilutional anemia and coagulopathy, which may lead to transfusions and tissue edema-related adverse outcomes. (See  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Avoid traditional liberal or fixed-volume approaches'</a>.)</p><p class="headingAnchor" id="H3882409062"><span class="h2">Acute normovolemic hemodilution</span><span class="headingEndMark"> — </span>ANH is a blood conservation technique appropriate for selected patients with normal initial hemoglobin levels who are expected to lose two or more units of blood (typically ≥1000 mL) during surgery. The technique involves removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement fluid. Details regarding technical considerations are addressed separately. (See  <a class="medical medical_review" href="/d/html/7936.html" rel="external">"Surgical blood conservation: Acute normovolemic hemodilution"</a>.)</p><p>The ANH technique is safe and generally used in healthy, young adults but can be used in other populations, especially those needing extracorporeal circulation. ANH with the blood maintained in a contiguous circuit with the circulation may also be a good option if blood transfusions are not an option; however, the patient's wishes must be determined prior to the procedure [<a href="#rid80">80</a>]. (See <a class="local">'Consents and advanced directives'</a> above and  <a class="medical medical_review" href="/d/html/7936.html" rel="external">"Surgical blood conservation: Acute normovolemic hemodilution", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H1848826462"><span class="h2">Maintenance of normothermia</span><span class="headingEndMark"> — </span>Hypothermia is avoided throughout the perioperative period in noncardiac surgical patients. Hypothermia causes coagulopathy due to impairment of platelet aggregation and reduced activity of enzymes in the coagulation cascade [<a href="#rid81">81-83</a>]. This combination of platelet and enzyme impairment typically reduces clot formation and increases perioperative blood loss and the need for transfusion [<a href="#rid83">83-85</a>]. In one meta-analysis, even mild (eg, 1°C) hypothermia increased blood loss by approximately 20 percent  (<a class="graphic graphic_figure graphicRef116135" href="/d/graphic/116135.html" rel="external">figure 1</a>) [<a href="#rid83">83</a>]. </p><p>A blood warmer should be used for transfusion of all thawed or refrigerator-temperature blood products (eg, red blood cell [RBC] units, plasma products, cryoprecipitate) to avoid hypothermia &lt;36°C, which can lead to coagulopathy, bleeding, and additional transfusions [<a href="#rid81">81,86-88</a>]. If necessary, other fluid and patient warming devices are routinely employed to maintain perioperative normothermia [<a href="#rid89">89-92</a>]. These may include warming all intravenous fluids with a commercially available blood warming device and application of upper- and lower-body forced-air warming devices and blankets. Prevention of perioperative hypothermia is discussed further in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Intraoperative hypothermia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Maintenance of normothermia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Hypothermia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Hypothermia'</a>.)</p><p></p><p class="headingAnchor" id="H111418635"><span class="h2">Surgical blood conservation techniques</span></p><p class="headingAnchor" id="H1981261491"><span class="h3">Minimally invasive surgical techniques</span><span class="headingEndMark"> — </span>Minimally invasive surgical techniques have been developed; these may decrease blood loss and need for transfusion compared with conventional open surgical procedures [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4716442"><span class="h3">Electrosurgery devices</span><span class="headingEndMark"> — </span>Adequate hemostasis during surgical dissection can be achieved by employing electrocautery to control bleeding from small vessels in most cases, as well as standard suturing techniques for larger vessels. These techniques are discussed separately. (See  <a class="medical medical_review" href="/d/html/2890.html" rel="external">"Overview of electrosurgery", section on 'Cutting and coagulation currents'</a>.)</p><p class="headingAnchor" id="H871962905"><span class="h3">Intraoperative blood salvage</span><span class="headingEndMark"> — </span>Unlike preoperative autologous donation (PAD) and acute normovolemic hemodilution (ANH), in which patient's blood is collected prior to occurrence of surgical blood loss, intraoperative blood salvage (also known as blood recovery) focuses on retrieving and salvaging blood that has already been shed and is otherwise lost. The collected blood is washed or filtered and returned back to the patient as transfusion is needed. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p>Blood salvage is generally safe and associated with a very low incidence of adverse events [<a href="#rid93">93</a>]. The technique can be used during surgery to retrieve intraoperative blood loss. Benefits are most significant in procedures with high blood losses (≥1000 mL) [<a href="#rid94">94,95</a>]. </p><p>In cardiac surgery, reinfusion of mediastinal blood after washing may be considered as part of a multimodal blood conservation strategy, particularly for patients who will not accept allogeneic blood products [<a href="#rid96">96,97</a>]. </p><p>Details regarding patient selection, specific indications, technical considerations, advantages, and potential complications of intraoperative blood salvage are discussed separately. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a> and  <a class="medical medical_review" href="/d/html/15798.html" rel="external">"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy", section on 'Intraoperative blood salvage'</a>.)</p><p class="headingAnchor" id="H38323726"><span class="h3">Topical hemostatic agents and tissue adhesives</span><span class="headingEndMark"> — </span>In selected cases, topical hemostatic agents, tissue adhesives, fibrin sealants, and autologous platelet gels are used as adjuncts to standard techniques and electrocautery to control bleeding. Topical application of agents that enhance coagulation allows dosing at the application site without systemic exposure. The mechanism of action, indications, and clinical applications of these adjuncts are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives"</a>.)</p><p class="headingAnchor" id="H510886067"><span class="h2">Systemic hemostatic agents</span><span class="headingEndMark"> — </span>Hemostatic agents may be used to reduce the risk of bleeding or to treat excessive bleeding due to an anticoagulant or other cause of impaired hemostasis.</p><p class="headingAnchor" id="H3095259769"><span class="h3">Antifibrinolytic agents</span><span class="headingEndMark"> — </span>The most commonly used intraoperative hemostatic agents are antifibrinolytic agents (eg, <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> [TXA] and epsilon-aminocaproic acid [EACA]). Efficacy in inhibiting fibrinolysis, potential adverse effects, and perioperative use of these agents for cardiac surgery with cardiopulmonary bypass (CPB) are discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/140949.html" rel="external">"Intraoperative use of antifibrinolytic agents"</a>.)</p><p>Prophylactic use of antifibrinolytics (primarily TXA) is also common during other major elective surgical procedures: </p><p class="bulletIndent1"><span class="glyph">●</span>Major orthopedic surgery (eg, total knee, hip, or shoulder arthroplasty, spine surgery) – (See  <a class="medical medical_review" href="/d/html/116322.html" rel="external">"Anesthesia for total knee arthroplasty", section on 'Antifibrinolytics'</a> and  <a class="medical medical_review" href="/d/html/7972.html" rel="external">"Total hip arthroplasty", section on 'Minimizing blood loss'</a> and  <a class="medical medical_review" href="/d/html/91785.html" rel="external">"Anesthesia for elective spine surgery in adults", section on 'Antifibrinolytics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver transplantation or resection – (See  <a class="medical medical_review" href="/d/html/94585.html" rel="external">"Liver transplantation: Anesthetic management", section on 'Administration of antifibrinolytic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major gynecologic surgery – (See  <a class="medical medical_review" href="/d/html/3301.html" rel="external">"Overview of preoperative evaluation and preparation for gynecologic surgery", section on 'Prophylactic tranexamic acid'</a>.)</p><p></p><p>Administration of TXA during nonelective surgery for trauma is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute traumatic brain injury – (See  <a class="medical medical_review" href="/d/html/94283.html" rel="external">"Anesthesia for patients with acute traumatic brain injury", section on 'Tranexamic acid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other trauma surgery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a> and  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Management of acute traumatic coagulopathy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/113837.html" rel="external">"Initial management of moderate to severe hemorrhage in the adult trauma patient", section on 'Antifibrinolytic agents'</a>.)</p><p></p><p>Use of TXA to treat peripartum hemorrhage is also discussed separately. (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer tranexamic acid'</a>.)</p><p class="headingAnchor" id="H705374958"><span class="h3">Desmopressin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">Desmopressin</a> (DDAVP) increases plasma levels of von Willebrand factor, factor VIII, and tissue-type plasminogen activator (tPA) by causing these factors to be released from platelets and endothelial cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and uses</strong> – In consultation with a hematologist, DDAVP is administered prophylactically for minor surgery or treatment of mild bleeding in selected patients with von Willebrand disease (VWD) or mild hemophilia A for whom a positive response to the drug has been demonstrated previously [<a href="#rid98">98</a>]  (<a class="graphic graphic_table graphicRef110532" href="/d/graphic/110532.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B", section on 'DDAVP for mild hemophilia A'</a> and  <a class="medical medical_review" href="/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'</a>.)</p><p></p><p class="bulletIndent1">DDAVP has also been administered to treat clinically significant intraoperative microvascular bleeding in patients with acquired platelet defects due to uremia or acquired von Willebrand syndrome (eg, due to chronic aortic stenosis or presence of a left ventricular assist device) [<a href="#rid51">51,99</a>]. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome", section on 'Treatment of acute bleeding'</a> and  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Acute life-threatening bleeding'</a>.)</p><p></p><p class="bulletIndent1">DDAVP may be beneficial in certain other perioperative settings (eg, intractable microvascular bleeding due to hypothermia, acidosis, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> use, CPB), but only small reductions in transfused RBC volume have been demonstrated [<a href="#rid38">38,100,101</a>]. Generalized perioperative use is not warranted [<a href="#rid19">19,38,51</a>]. (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a> and  <a class="medical medical_review" href="/d/html/122792.html" rel="external">"Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Desmopressin'</a> and  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Other agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The DDAVP dose is 0.3 mcg/kg, administered intravenously by slow infusion over 30 minutes to minimize hypertension, hypotension, and flushing  (<a class="graphic graphic_table graphicRef110532" href="/d/graphic/110532.html" rel="external">table 7</a>). Tachyphylaxis typically develops after the second dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks</strong> – DDAVP can cause hypertension, hypotension, flushing, fluid overload, hyponatremia (which may cause seizures if close attention to free water restriction is not used), and rare thrombotic events  (<a class="graphic graphic_table graphicRef110532" href="/d/graphic/110532.html" rel="external">table 7</a>). Monitoring of serum sodium is prudent in patients receiving more than one or two doses.</p><p></p><p class="headingAnchor" id="H2242894032"><span class="h3">Clotting factors</span><span class="headingEndMark"> — </span>Perioperative use of clotting factors including <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a>, prothrombin complex concentrates (PCCs), or recombinant activated factor VII (rFVIIa) is discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors"</a>.)</p><p class="headingAnchor" id="H1096442229"><span class="h1">POSTOPERATIVE STRATEGIES</span><span class="headingEndMark"> — </span>Restrictive transfusion thresholds and individualized goal-directed treatment of coagulopathy with bleeding remain important in the postoperative period [<a href="#rid4">4,102</a>].</p><p class="headingAnchor" id="H2913260081"><span class="h2">Close monitoring for bleeding</span><span class="headingEndMark"> — </span>Postoperative bleeding is associated with mortality risk and increased health care costs [<a href="#rid103">103</a>]. During the first few hours following major surgical procedures, patients should be closely monitored to detect signs of persistent bleeding of unacceptable quantity and tempo [<a href="#rid4">4</a>]. </p><p>Medical causes of bleeding should be investigated and treated. </p><p>Return to the operating room for surgical re-exploration and intervention may be necessary based on the amount, tempo, presumed location of bleeding, and potential for a surgical/anatomic cause [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H1920440186"><span class="h2">Minimize phlebotomy</span><span class="headingEndMark"> — </span>Excessive diagnostic blood draws should be avoided since this can contribute significantly to blood loss and development of hospital-acquired anemia [<a href="#rid4">4,37,105-108</a>]. Perioperative blood sampling for laboratory tests should be minimized (eg, by using smaller collection tubes when feasible). Standing orders for laboratory tests are generally avoided; rather, tests are ordered if indicated. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Minimize blood loss'</a>.)</p><p class="headingAnchor" id="H130058358"><span class="h2">Management of postoperative anemia</span><span class="headingEndMark"> — </span>Postoperative anemia is common due to exacerbation of preoperative anemia, blood loss during surgery, and excessive postoperative phlebotomies [<a href="#rid31">31,104,106-108</a>]. </p><p>Anemia may be further aggravated by reduced erythropoietin (EPO) production due to inflammatory mediators, blunted bone marrow response to EPO, and decreased iron availability, similar to patients with critical illness [<a href="#rid104">104,109,110</a>]. Anemia may significantly impact postoperative recovery and is associated with increased risk of mortality and morbidity, delayed hospital discharge, and increased costs [<a href="#rid107">107</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and treatment</strong> – When anemia is noted in the postoperative period, a diagnostic workup is performed to determine its cause, as illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef131161" href="/d/graphic/131161.html" rel="external">algorithm 2</a>), incorporating information from the workup done in the preoperative period (eg, iron studies) [<a href="#rid104">104,111</a>]. As with preoperative anemia, postoperative anemia should not be overlooked or neglected [<a href="#rid4">4,39,104</a>]. Treatment strategies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treat iron deficiency</strong> – Since postoperative anemia is usually due to surgical blood loss, iron studies are usually appropriate, especially if anemia and/or microcytosis persist for more than one to two weeks. Treatment of postoperative iron deficiency may involve administration of intravenous iron in patients who cannot take oral medications [<a href="#rid39">39,112-116</a>]. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Red blood cell transfusion</strong> – Transfusion may be necessary if postoperative hemoglobin is below a threshold (&lt;7 to 8 g/dL in most populations) and/or if there is severe ongoing bleeding with expected severe anemia, or if there are signs of hemodynamic instability or tissue hypoxia thought to be due to severe anemia. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Thresholds for specific patient populations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitor resolution</strong> – All patients with postoperative anemia should have planned follow-up to determine if anemia has resolved or persists  (<a class="graphic graphic_algorithm graphicRef131161" href="/d/graphic/131161.html" rel="external">algorithm 2</a>).</p><p></p><p class="headingAnchor" id="H2354751535"><span class="h1">ANEMIA CLINICAL VIGNETTES</span><span class="headingEndMark"> — </span>The following hypothetical clinical case examples illustrate the principles discussed in this topic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency surgery requiring transfusion</strong> – A 40-year-old woman presents to the emergency department following a motor vehicle crash and requires emergency splenectomy. As she arrives in the operating room, report comes from the emergency department that her complete blood count (CBC) is abnormal with mild pancytopenia (white blood count 3000/microL; hemoglobin 8 g/dL; platelet count 70,000/microL). Surgery is performed, with point of care testing revealing a decrease in hemoglobin to 6 g/dL; hemostasis is maintained. She receives a total of two units of red blood cells intraoperatively, administered in one unit increments with hemoglobin determination after the first unit showing a hemoglobin of 6.2 g/dL. Postoperatively she is evaluated by the consulting hematologist to evaluate the cause of pancytopenia.</p><p></p><p class="bulletIndent1">This case illustrates a setting in which the need for emergency surgery does not allow sufficient time to perform a full evaluation of the cause of anemia; clinical judgment determines that transfusion of one unit at a time may be required in the short term; and specialist evaluation is required prior to discharge from the hospital.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correction of iron deficiency prior to elective surgery</strong> – A 52-year-old man with no underlying medical conditions except for chronic knee pain due to a prior sports injury is seen two weeks preoperatively for knee replacement surgery. His report of recent fatigue and mild dyspnea on exertion prompts testing of his hemoglobin level, which is found to be low at 10 g/dL. Review of his CBC reveals microcytosis (mean corpuscular volume [MCV], 79 fL), and iron studies reveal iron deficiency with a ferritin level of 10 ng/mL, consistent with iron deficiency anemia. He is treated with iron and undergoes colonoscopy, which identifies a large bleeding polyp that is removed. Iron replacement is continued. Four weeks later, his hemoglobin has risen to 14 g/dL with resolution of his fatigue and dyspnea.</p><p></p><p class="bulletIndent1">After treatment of iron deficiency anemia, he undergoes knee replacement, with antifibrinolytic therapy administered during the procedure. Blood loss is approximately 500 mL, and his postoperative hemoglobin level is 12 g/dL. Transfusion is unnecessary and thus avoided. With the help of a new primary care doctor, he continues iron to completely replete iron stores, and he undergoes regular screening colonoscopy. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p></p><p class="bulletIndent1">This case illustrates the importance of treating correctable causes of anemia in the preoperative period to minimize the likelihood of transfusion, the use of intraoperative antifibrinolytic therapy, and the need for postoperative follow-up. Surgical blood loss may have been further reduced by implementing blood cell salvage techniques.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic inflammatory conditions causing anemia</strong> – A 65-year-old woman with type 2 diabetes mellitus has been highly adherent with therapy and eats a well-balanced diet but continues to have mild anemia due to her underlying diabetes and high body mass index (ie, anemia of chronic disease/anemia of inflammation). Her primary clinician has performed iron studies and testing for <a class="drug drug_general" data-topicid="9302" href="/d/drug information/9302.html" rel="external">vitamin B12</a> deficiency and found her levels to be adequate. She has decided to pursue laparoscopic bariatric surgery and is seen two weeks preoperatively. The preoperative evaluation includes review of her CBC obtained one week earlier by her primary clinician, who documents a mild anemia with a hemoglobin of 11.5 g/dL with normal red blood cell indices. Discussion regarding possible postponement of surgery among the patient, primary care clinician, surgeon, and anesthesiologist, resulted in a decision to proceed as scheduled in order to help treat the underlying conditions that may be contributing to her anemia. Appropriate intraoperative strategies are used to avoid exacerbation of anemia (eg, fluid and temperature management, fastidious hemostasis during surgical dissection). No transfusions are administered.</p><p></p><p class="bulletIndent1">This case illustrates the need for individual evaluation of patients with chronic conditions that result in anemia, in order to exercise good clinical judgment regarding decisions to proceed with a specific surgical procedure.</p><p></p><p>The underlying cause of the anemia was addressed in each of these cases. What differs was the decision regarding whether to proceed with surgery as planned or to delay surgery to allow treatment of anemia.</p><p class="headingAnchor" id="H430164755"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H3871555104"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient blood management</strong> – Patient blood management (PBM) is a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient’s own blood, while promoting patient safety  (<a class="graphic graphic_table graphicRef120192" href="/d/graphic/120192.html" rel="external">table 1</a>). (See <a class="local">'Goals of patient blood management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative strategies</strong> – The preanesthetic consultation addresses risks for bleeding and possible interventions to minimize transfusions. The history focuses on comorbidities and bleeding history. A baseline hemoglobin is obtained for patients undergoing major surgery with expected significant blood loss (&gt;10 percent chance of requiring transfusion or &gt;500 mL blood loss), those &gt;65 years old (except for minor procedures), or if preoperative anemia is suspected  (<a class="graphic graphic_algorithm graphicRef120496" href="/d/graphic/120496.html" rel="external">algorithm 1</a>). Additional laboratory testing for patients with a possible bleeding disorder includes prothrombin time (PT) with international normalized ratio (INR), activated partial thromboplastin time (aPTT), and platelet count. (See <a class="local">'Preoperative strategies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia</strong> – Depending on the cause, severity, urgency of the procedure, and anticipated blood loss, surgery is postponed when feasible to provide appropriate treatment  (<a class="graphic graphic_algorithm graphicRef120496" href="/d/graphic/120496.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment of anemia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Iron</strong> – Iron deficiency (with or without anemia) should be treated with iron, typically two to four weeks before surgery. Intravenous (IV) iron is an option if more urgent correction is needed or if oral iron is not well tolerated or ineffective. (See <a class="local">'Iron deficiency anemia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Erythropoietin</strong> – Decisions to administer erythropoietin (EPO) are individualized. For anemia of chronic disease/anemia of inflammation, we typically administer preoperative EPO (with supplemental iron to avoid functional iron deficiency) if hemoglobin is &lt;12 g/dL before scheduled noncardiac surgery with expected blood loss &gt;500 mL, or if hemoglobin &lt;13 g/dL before cardiac surgery. (See <a class="local">'Use of erythropoietin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Transfusions</strong> – For urgent or emergency surgery, it may not be possible to treat all conditions contributing to anemia; transfusions may be needed in some cases. (See <a class="local">'Urgent and emergency surgical procedures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombocytopenia or platelet dysfunction</strong> – Safe platelet counts for most surgeries are &gt;50,000/microL (&gt;100,000/microL for neurosurgery or ocular surgery). For immune thrombocytopenia (ITP), the platelet count may be raised using glucocorticoids or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) if below a safe threshold. For other causes of thrombocytopenia or if there is insufficient time to treat the underlying cause, platelet transfusions may be needed. (See <a class="local">'Management of thrombocytopenia or platelet dysfunction'</a> above and  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antithrombotic medications</strong> – Preoperative discussions with the surgeon and primary clinician determine management based on bleeding risk for the procedure versus thrombosis risk if anticoagulants are discontinued or reversed. (See <a class="local">'Management of specific hemostatic disorders'</a> above and <a class="local">'Management of medications affecting hemostasis'</a> above and  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advance directives</strong> – Patient preferences and acceptance of transfusions and/or blood conservation modalities should be discussed and documented. (See <a class="local">'Consents and advanced directives'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraoperative strategies</strong> – Restrictive transfusion thresholds should be used in stable patients. Intraoperative strategies include avoiding large volumes of crystalloid solution, avoiding hypothermia, and using electrosurgery or topical hemostatic agents when appropriate. Blood conservation techniques such as intraoperative blood salvage or acute normovolemic hemodilution (ANH) may be appropriate in selected cases. (See <a class="local">'Fluid management'</a> above and <a class="local">'Maintenance of normothermia'</a> above and <a class="local">'Surgical blood conservation techniques'</a> above.)</p><p></p><p class="bulletIndent1">Antifibrinolytic agents are routinely used in cardiac surgery with cardiopulmonary bypass (CPB) and selected noncardiac surgical procedures associated with significant blood loss. (See <a class="local">'Antifibrinolytic agents'</a> above.) </p><p></p><p class="bulletIndent1">Intraoperative transfusion and administration of clotting factor products are discussed separately. (See  <a class="medical medical_review" href="/d/html/112610.html" rel="external">"Intraoperative transfusion and administration of clotting factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative strategies</strong> – Patients should be monitored for persistent bleeding. Blood sampling should be minimized. For postoperative anemia, a diagnostic workup is performed and treatment initiated as appropriate  (<a class="graphic graphic_algorithm graphicRef131161" href="/d/graphic/131161.html" rel="external">algorithm 2</a>). (See <a class="local">'Postoperative strategies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. J Cardiothorac Vasc Anesth 2021; 35:2569.</a></li><li><a class="nounderline abstract_t">Shander A, Hardy JF, Ozawa S, et al. A Global Definition of Patient Blood Management. Anesth Analg 2022; 135:476.</a></li><li><a class="nounderline abstract_t">Hameed I, Cifu AS, Geirsson A. Blood Management in High-risk Surgery. JAMA 2022; 327:578.</a></li><li><a class="nounderline abstract_t">Spahn DR, Muñoz M, Klein AA, et al. Patient Blood Management: Effectiveness and Future Potential. Anesthesiology 2020; 133:212.</a></li><li><a class="nounderline abstract_t">Palmer AJR, Gagné S, Fergusson DA, et al. Blood Management for Elective Orthopaedic Surgery. J Bone Joint Surg Am 2020; 102:1552.</a></li><li><a class="nounderline abstract_t">Desai N, Schofield N, Richards T. Perioperative Patient Blood Management to Improve Outcomes. Anesth Analg 2018; 127:1211.</a></li><li class="breakAll">Society for the Advancement of Blood Management (SABM). Available at: https://www.sabm.org/ (Accessed on July 11, 2018).</li><li><a class="nounderline abstract_t">Meybohm P, Herrmann E, Steinbicker AU, et al. Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design. Ann Surg 2016; 264:203.</a></li><li><a class="nounderline abstract_t">Irving AH, Harris A, Petrie D, et al. Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. J Thorac Cardiovasc Surg 2020; 160:437.</a></li><li><a class="nounderline abstract_t">Pavenski K, Howell A, Mazer CD, et al. ONTraC: A 20-Year History of a Successfully Coordinated Provincewide Patient Blood Management Program: Lessons Learned and Goals Achieved. Anesth Analg 2022; 135:448.</a></li><li><a class="nounderline abstract_t">Trentino KM, Mace H, Symons K, et al. Associations of a Preoperative Anemia and Suboptimal Iron Stores Screening and Management Clinic in Colorectal Surgery With Hospital Cost, Reimbursement, and Length of Stay: A Net Cost Analysis. Anesth Analg 2021; 132:344.</a></li><li><a class="nounderline abstract_t">Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006; 13:462.</a></li><li><a class="nounderline abstract_t">Shander A, Isbister J, Gombotz H. Patient blood management: the global view. Transfusion 2016; 56 Suppl 1:S94.</a></li><li><a class="nounderline abstract_t">Shander A, Goobie SM, Warner MA, et al. Essential Role of Patient Blood Management in a Pandemic: A Call for Action. Anesth Analg 2020; 131:74.</a></li><li><a class="nounderline abstract_t">Gehrie EA, Frank SM, Goobie SM. Balancing Supply and Demand for Blood during the COVID-19 Pandemic. Anesthesiology 2020; 133:16.</a></li><li class="breakAll">Pandemics and patient blood management (PBM), Produced by the Committee on Patient Blood Management updeated March 27, 2020. American Society of Anesthesiologists https://www.https://www.asahq.org/in-the-spotlight/coronavirus-covid-19-information/pandemics-and-patient-blood-management (Accessed on July 20, 2020).</li><li><a class="nounderline abstract_t">Baron DM, Franchini M, Goobie SM, et al. Patient blood management during the COVID-19 pandemic: a narrative review. Anaesthesia 2020; 75:1105.</a></li><li><a class="nounderline abstract_t">Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S. Pre-operative haematological assessment in patients scheduled for major surgery. Anaesthesia 2016; 71 Suppl 1:19.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.</a></li><li><a class="nounderline abstract_t">Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72:233.</a></li><li><a class="nounderline abstract_t">Steinbicker AU. Role of anesthesiologists in managing perioperative anemia. Curr Opin Anaesthesiol 2019; 32:64.</a></li><li><a class="nounderline abstract_t">Okocha O, Dand H, Avram MJ, Sweitzer B. An Effective and Efficient Testing Protocol for Diagnosing Iron-deficiency Anemia Preoperatively. Anesthesiology 2020; 133:109.</a></li><li><a class="nounderline abstract_t">Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med 2014; 34:453.</a></li><li><a class="nounderline abstract_t">Loizou E, Mayhew DJ, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia 2018; 73:1557.</a></li><li><a class="nounderline abstract_t">Committee on Standards and Practice Parameters, Apfelbaum JL, Connis RT, et al. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology 2012; 116:522.</a></li><li><a class="nounderline abstract_t">Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140:496.</a></li><li><a class="nounderline abstract_t">De Hert S, Imberger G, Carlisle J, et al. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011; 28:684.</a></li><li><a class="nounderline abstract_t">Matzek LJ, Hanson AC, Schulte PJ, et al. The Prevalence and Clinical Significance of Preoperative Thrombocytopenia in Adults Undergoing Elective Surgery: An Observational Cohort Study. Anesth Analg 2021; 132:836.</a></li><li><a class="nounderline abstract_t">Dhir A, Tempe DK. Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence. J Cardiothorac Vasc Anesth 2018; 32:2726.</a></li><li><a class="nounderline abstract_t">Munting KE, Klein AA. Optimisation of pre-operative anaemia in patients before elective major surgery - why, who, when and how? Anaesthesia 2019; 74 Suppl 1:49.</a></li><li><a class="nounderline abstract_t">Warner MA, Shore-Lesserson L, Shander A, et al. Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care. Anesth Analg 2020; 130:1364.</a></li><li><a class="nounderline abstract_t">Hare GMT, Mazer CD. Anemia: Perioperative Risk and Treatment Opportunity. Anesthesiology 2021; 135:520.</a></li><li><a class="nounderline abstract_t">Guinn NR, Schwartz J, Arora RC, et al. Perioperative Quality Initiative and Enhanced Recovery After Surgery-Cardiac Society Consensus Statement on the Management of Preoperative Anemia and Iron Deficiency in Adult Cardiac Surgery Patients. Anesth Analg 2022; 135:532.</a></li><li><a class="nounderline abstract_t">Ganz T. Anemia of Inflammation. N Engl J Med 2019; 381:1148.</a></li><li><a class="nounderline abstract_t">Ellermann I, Bueckmann A, Eveslage M, et al. Treating Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation. Anesth Analg 2018; 127:1202.</a></li><li><a class="nounderline abstract_t">Guinn NR, Guercio JR, Hopkins TJ, et al. How do we develop and implement a preoperative anemia clinic designed to improve perioperative outcomes and reduce cost? Transfusion 2016; 56:297.</a></li><li><a class="nounderline abstract_t">Burns CD, Brown JP, Corwin HL, et al. Special Report From the Society for the Advancement of Blood Management: The Choosing Wisely Campaign. Anesth Analg 2019; 129:1381.</a></li><li><a class="nounderline abstract_t">Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.</a></li><li><a class="nounderline abstract_t">Shander A, Kaufman M, Goodnough LT. How I treat anemia in the perisurgical setting. Blood 2020; 136:814.</a></li><li><a class="nounderline abstract_t">Kotzé A, Harris A, Baker C, et al. British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia. Br J Haematol 2015; 171:322.</a></li><li><a class="nounderline abstract_t">Rineau E, Stoyanov A, Samson E, et al. Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron? Anesth Analg 2017; 125:1597.</a></li><li><a class="nounderline abstract_t">Lim J, Miles L, Litton E. Intravenous Iron Therapy in Patients Undergoing Cardiovascular Surgery: A Narrative Review. J Cardiothorac Vasc Anesth 2018; 32:1439.</a></li><li><a class="nounderline abstract_t">Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017; 15:422.</a></li><li><a class="nounderline abstract_t">Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev 2013; 27:221.</a></li><li><a class="nounderline abstract_t">Keeler BD, Dickson EA, Simpson JA, et al. The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial. Anaesthesia 2019; 74:714.</a></li><li><a class="nounderline abstract_t">Richards T, Baikady RR, Clevenger B, et al. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet 2020; 396:1353.</a></li><li><a class="nounderline abstract_t">Shander A, Muñoz M, Spahn DR. Intravenous iron for severe iron deficiency anaemia. Br J Anaesth 2018; 121:342.</a></li><li><a class="nounderline abstract_t">Biboulet P, Bringuier S, Smilevitch P, et al. Preoperative Epoetin-α with Intravenous or Oral Iron for Major Orthopedic Surgery: A Randomized Controlled Trial. Anesthesiology 2018; 129:710.</a></li><li><a class="nounderline abstract_t">Song JW, Soh S, Shim JK, et al. Effect of Perioperative Intravenous Iron Supplementation for Complex Cardiac Surgery on Transfusion Requirements: A Randomized, Double-blinded Placebo-controlled Trial. Ann Surg 2022; 275:232.</a></li><li><a class="nounderline abstract_t">Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA 2019; 321:983.</a></li><li><a class="nounderline abstract_t">Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53:79.</a></li><li><a class="nounderline abstract_t">Kaufner L, von Heymann C, Henkelmann A, et al. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery. Cochrane Database Syst Rev 2020; 8:CD012451.</a></li><li><a class="nounderline abstract_t">Cho BC, Serini J, Zorrilla-Vaca A, et al. Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results From a Systematic Review and Meta-analysis. Anesth Analg 2019; 128:981.</a></li><li><a class="nounderline abstract_t">Spahn DR, Schoenrath F, Spahn GH, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. Lancet 2019; 393:2201.</a></li><li><a class="nounderline abstract_t">Rössler J, Hegemann I, Schoenrath F, et al. Efficacy of quadruple treatment on different types of pre-operative anaemia: secondary analysis of a randomised controlled trial. Anaesthesia 2020; 75:1039.</a></li><li><a class="nounderline abstract_t">Vassallo R, Goldman M, Germain M, et al. Preoperative autologous blood donation: Waning indications in an era of improved blood safety. Transfus Med Rev 2015; 29:268.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol 2018; 182:106.</a></li><li><a class="nounderline abstract_t">Mishra PK, Thekkudan J, Sahajanandan R, et al. The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting. Ann Card Anaesth 2015; 18:45.</a></li><li><a class="nounderline abstract_t">Ranucci M, Baryshnikova E For The Surgical And Clinical Outcome Research Score Group. The interaction between preoperative platelet count and function and its relationship with postoperative bleeding in cardiac surgery. Platelets 2017; 28:794.</a></li><li><a class="nounderline abstract_t">Nagarsheth NP, Gupta N, Gupta A, et al. Responses of advanced directives by Jehovah's Witnesses on a gynecologic oncology service. J Blood Med 2015; 6:17.</a></li><li><a class="nounderline abstract_t">Klein AA, Bailey CR, Charlton A, et al. Association of Anaesthetists: anaesthesia and peri-operative care for Jehovah's Witnesses and patients who refuse blood. Anaesthesia 2019; 74:74.</a></li><li><a class="nounderline abstract_t">Guinn NR, Resar LMS, Frank SM. Perioperative Management of Patients for Whom Transfusion Is Not an Option. Anesthesiology 2021; 134:939.</a></li><li><a class="nounderline abstract_t">Tan GM, Guinn NR, Frank SM, Shander A. Proceedings From the Society for Advancement of Blood Management Annual Meeting 2017: Management Dilemmas of the Surgical Patient-When Blood Is Not an Option. Anesth Analg 2019; 128:144.</a></li><li><a class="nounderline abstract_t">Shander A, Goodnough LT. Management of anemia in patients who decline blood transfusion. Am J Hematol 2018; 93:1183.</a></li><li><a class="nounderline abstract_t">Husarova V, Donnelly G, Doolan A, et al. Preferences of Jehovah's Witnesses regarding haematological supports in an obstetric setting: experience of a single university teaching hospital. Int J Obstet Anesth 2016; 25:53.</a></li><li><a class="nounderline abstract_t">Frank SM, Pippa A, Sherd I, et al. Methods of Bloodless Care, Clinical Outcomes, and Costs for Adult Patients Who Decline Allogeneic Transfusions. Anesth Analg 2022; 135:576.</a></li><li><a class="nounderline abstract_t">Jahr JS, Guinn NR, Lowery DR, et al. Blood Substitutes and Oxygen Therapeutics: A Review. Anesth Analg 2021; 132:119.</a></li><li><a class="nounderline abstract_t">Boyd-Carson H, Shah A, Sugavanam A, et al. The association of pre-operative anaemia with morbidity and mortality after emergency laparotomy. Anaesthesia 2020; 75:904.</a></li><li><a class="nounderline abstract_t">Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019; 23:98.</a></li><li><a class="nounderline abstract_t">Blaine KP, Steurer MP. Viscoelastic Monitoring to Guide the Correction of Perioperative Coagulopathy and Massive Transfusion in Patients with Life-Threatening Hemorrhage. Anesthesiol Clin 2019; 37:51.</a></li><li><a class="nounderline abstract_t">Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113:1205.</a></li><li><a class="nounderline abstract_t">Chatrath V, Khetarpal R, Ahuja J. Fluid management in patients with trauma: Restrictive versus liberal approach. J Anaesthesiol Clin Pharmacol 2015; 31:308.</a></li><li><a class="nounderline abstract_t">Langer A, Connors JM. Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. Anesthesiology 2020; 133:223.</a></li><li><a class="nounderline abstract_t">Tao J, Oprea AD. Updates in periprocedural management of direct oral anticoagulants. Curr Opin Anaesthesiol 2020; 33:423.</a></li><li><a class="nounderline abstract_t">Levy JH, Douketis J, Steiner T, et al. Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. Anesthesiology 2018; 129:1171.</a></li><li><a class="nounderline abstract_t">Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 2011; 51:2269.</a></li><li><a class="nounderline abstract_t">Estcourt LJ, Malouf R, Doree C, et al. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. Cochrane Database Syst Rev 2018; 9:CD012779.</a></li><li><a class="nounderline abstract_t">Estcourt LJ, Desborough M, Hopewell S, et al. Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia. Cochrane Database Syst Rev 2015; 2015.</a></li><li><a class="nounderline abstract_t">Filipescu DC, Stefan MG, Valeanu L, Popescu WM. Perioperative management of antiplatelet therapy in noncardiac surgery. Curr Opin Anaesthesiol 2020; 33:454.</a></li><li><a class="nounderline abstract_t">Levy JH, Koster A, Quinones QJ, et al. Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology 2018; 128:657.</a></li><li><a class="nounderline abstract_t">Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.</a></li><li><a class="nounderline abstract_t">Valeri CR, Khabbaz K, Khuri SF, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992; 104:108.</a></li><li><a class="nounderline abstract_t">Rajagopalan S, Mascha E, Na J, Sessler DI. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology 2008; 108:71.</a></li><li><a class="nounderline abstract_t">Reed RL 2nd, Johnson TD, Hudson JD, Fischer RP. The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992; 33:465.</a></li><li><a class="nounderline abstract_t">Lester ELW, Fox EE, Holcomb JB, et al. The impact of hypothermia on outcomes in massively transfused patients. J Trauma Acute Care Surg 2019; 86:458.</a></li><li><a class="nounderline abstract_t">Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.</a></li><li><a class="nounderline abstract_t">Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.</a></li><li><a class="nounderline abstract_t">Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.</a></li><li><a class="nounderline abstract_t">John M, Ford J, Harper M. Peri-operative warming devices: performance and clinical application. Anaesthesia 2014; 69:623.</a></li><li><a class="nounderline abstract_t">Perl T, Bräuer A, Quintel M. Prevention of perioperative hypothermia with forced-air warming systems and upper-body blankets. Surg Technol Int 2006; 15:19.</a></li><li><a class="nounderline abstract_t">Madrid E, Urrútia G, Roqué i Figuls M, et al. Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults. Cochrane Database Syst Rev 2016; 4:CD009016.</a></li><li><a class="nounderline abstract_t">Sessler DI. Perioperative thermoregulation and heat balance. Lancet 2016; 387:2655.</a></li><li><a class="nounderline abstract_t">DeAndrade D, Waters JH, Triulzi DJ, et al. Very low rate of patient-related adverse events associated with the use of intraoperative cell salvage. Transfusion 2016; 56:2768.</a></li><li><a class="nounderline abstract_t">Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010; :CD001888.</a></li><li><a class="nounderline abstract_t">Meybohm P, Choorapoikayil S, Wessels A, et al. Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore) 2016; 95:e4490.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27.</a></li><li><a class="nounderline abstract_t">Leebeek FWG, Eikenboom JCJ. Von Willebrand's Disease. N Engl J Med 2017; 376:701.</a></li><li><a class="nounderline abstract_t">Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.</a></li><li><a class="nounderline abstract_t">Desborough MJ, Oakland K, Brierley C, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev 2017; 7:CD001884.</a></li><li><a class="nounderline abstract_t">Desborough MJ, Oakland KA, Landoni G, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2017; 15:263.</a></li><li><a class="nounderline abstract_t">Will ND, Kor DJ, Frank RD, et al. Initial Postoperative Hemoglobin Values and Clinical Outcomes in Transfused Patients Undergoing Noncardiac Surgery. Anesth Analg 2019; 129:819.</a></li><li><a class="nounderline abstract_t">Bellomy ML, Engoren MC, Martin BJ, et al. The Attributable Mortality of Postoperative Bleeding Exceeds the Attributable Mortality of Postoperative Venous Thromboembolism. Anesth Analg 2021; 132:82.</a></li><li><a class="nounderline abstract_t">Muñoz M, Acheson AG, Bisbe E, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia 2018; 73:1418.</a></li><li><a class="nounderline abstract_t">Salisbury AC, Reid KJ, Alexander KP, et al. Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med 2011; 171:1646.</a></li><li><a class="nounderline abstract_t">Matzek LJ, LeMahieu AM, Madde NR, et al. A Contemporary Analysis of Phlebotomy and Iatrogenic Anemia Development Throughout Hospitalization in Critically Ill Adults. Anesth Analg 2022; 135:501.</a></li><li><a class="nounderline abstract_t">Koch CG, Li L, Sun Z, et al. From Bad to Worse: Anemia on Admission and Hospital-Acquired Anemia. J Patient Saf 2017; 13:211.</a></li><li><a class="nounderline abstract_t">Hatton SP, Smith AF. Postoperative anaemia: balancing the risks of anaemia and transfusion. Anaesthesia 2018; 73:1313.</a></li><li><a class="nounderline abstract_t">van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28:2773.</a></li><li><a class="nounderline abstract_t">Muñoz M, García-Erce JA, Remacha ÁF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011; 64:287.</a></li><li><a class="nounderline abstract_t">Shander A, Goodnough LT. From Tolerating Anemia to Treating Anemia. Ann Intern Med 2019; 170:125.</a></li><li><a class="nounderline abstract_t">Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol 2016; 3:e415.</a></li><li><a class="nounderline abstract_t">Kim YW, Bae JM, Park YK, et al. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial. JAMA 2017; 317:2097.</a></li><li><a class="nounderline abstract_t">Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang 2017; 112:219.</a></li><li><a class="nounderline abstract_t">Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med 2019; 32:2797.</a></li><li><a class="nounderline abstract_t">Xu H, Duan Y, Yuan X, et al. Intravenous Iron Versus Placebo in the Management of Postoperative Functional Iron Deficiency Anemia in Patients Undergoing Cardiac Valvular Surgery: A Prospective, Single-Blinded, Randomized Controlled Trial. J Cardiothorac Vasc Anesth 2019; 33:2941.</a></li></ol></div><div id="topicVersionRevision">Topic 94347 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217578" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35147598" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A Global Definition of Patient Blood Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35133425" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Blood Management in High-risk Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32108683" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Patient Blood Management: Effectiveness and Future Potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558663" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blood Management for Elective Orthopaedic Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29064875" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Perioperative Patient Blood Management to Improve Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29064875" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Perioperative Patient Blood Management to Improve Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27163948" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711621" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977355" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ONTraC: A 20-Year History of a Successfully Coordinated Provincewide Patient Blood Management Program: Lessons Learned and Goals Achieved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33105276" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Associations of a Preoperative Anemia and Suboptimal Iron Stores Screening and Management Clinic in Colorectal Surgery With Hospital Cost, Reimbursement, and Length of Stay: A Net Cost Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Objectives and limitations of bloodless medical care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001367" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patient blood management: the global view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243296" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Essential Role of Patient Blood Management in a Pandemic: A Call for Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32550680" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Balancing Supply and Demand for Blood during the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32550680" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Balancing Supply and Demand for Blood during the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339260" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Patient blood management during the COVID-19 pandemic: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26620143" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pre-operative haematological assessment in patients scheduled for major surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545654" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27996086" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : International consensus statement on the peri-operative management of anaemia and iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531608" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of anesthesiologists in managing perioperative anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205552" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An Effective and Efficient Testing Protocol for Diagnosing Iron-deficiency Anemia Preoperatively.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168937" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30315725" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Implications of deranged activated partial thromboplastin time for anaesthesia and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22273990" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275427" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885981" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433115" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Prevalence and Clinical Significance of Preoperative Thrombocytopenia in Adults Undergoing Elective Surgery: An Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307702" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30604424" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Optimisation of pre-operative anaemia in patients before elective major surgery - why, who, when and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32167979" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34197591" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anemia: Perioperative Risk and Treatment Opportunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977363" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perioperative Quality Initiative and Enhanced Recovery After Surgery-Cardiac Society Consensus Statement on the Management of Preoperative Anemia and Iron Deficiency in Adult Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532961" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anemia of Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29944518" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treating Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26592207" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : How do we develop and implement a preoperative anemia clinic designed to improve perioperative outcomes and reduce cost?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517679" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Special Report From the Society for the Advancement of Blood Management: The Choosing Wisely Campaign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556314" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : How I treat anemia in the perisurgical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343392" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28514321" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246691" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravenous Iron Therapy in Patients Undergoing Cardiovascular Surgery: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28880842" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Current misconceptions in diagnosis and management of iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24135037" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30963552" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32896294" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032871" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intravenous iron for severe iron deficiency anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30074935" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preoperative Epoetin-αwith Intravenous or Oral Iron for Major Orthopedic Surgery: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34171864" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of Perioperative Intravenous Iron Supplementation for Complex Cardiac Surgery on Transfusion Requirements: A Randomized, Double-blinded Placebo-controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860564" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029100" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790892" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30649068" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results From a Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31036337" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32342498" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of quadruple treatment on different types of pre-operative anaemia: secondary analysis of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26006319" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Preoperative autologous blood donation: Waning indications in an era of improved blood safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29767837" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Romiplostim for the management of perioperative thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566711" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28277058" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The interaction between preoperative platelet count and function and its relationship with postoperative bleeding in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565911" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Responses of advanced directives by Jehovah's Witnesses on a gynecologic oncology service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30270470" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Association of Anaesthetists: anaesthesia and peri-operative care for Jehovah's Witnesses and patients who refuse blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857295" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Perioperative Management of Patients for Whom Transfusion Is Not an Option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29958216" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Proceedings From the Society for Advancement of Blood Management Annual Meeting 2017: Management Dilemmas of the Surgical Patient-When Blood Is Not an Option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30033541" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management of anemia in patients who decline blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597403" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preferences of Jehovah's Witnesses regarding haematological supports in an obstetric setting: experience of a single university teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977366" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Methods of Bloodless Care, Clinical Outcomes, and Costs for Adult Patients Who Decline Allogeneic Transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30925560" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Blood Substitutes and Oxygen Therapeutics: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32315080" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The association of pre-operative anaemia with morbidity and mortality after emergency laparotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917843" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711233" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Viscoelastic Monitoring to Guide the Correction of Perioperative Coagulopathy and Massive Transfusion in Patients with Life-Threatening Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20881594" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26330707" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fluid management in patients with trauma: Restrictive versus liberal approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217870" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371643" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Updates in periprocedural management of direct oral anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30157037" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517892" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30221749" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prophylactic platelet transfusions prior to surgery for people with a low platelet count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26814707" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371645" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Perioperative management of antiplatelet therapy in noncardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29200009" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Antifibrinolytic Therapy and Perioperative Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15211129" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614195" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156884" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effects of mild perioperative hypothermia on blood loss and transfusion requirement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404519" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The disparity between hypothermic coagulopathy and clotting studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30444856" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The impact of hypothermia on outcomes in massively transfused patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14608161" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849817" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381514" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24720346" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Peri-operative warming devices: performance and clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17029156" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prevention of perioperative hypothermia with forced-air warming systems and upper-body blankets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27098439" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26775126" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Perioperative thermoregulation and heat balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27614051" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Very low rate of patient-related adverse events associated with the use of intraoperative cell salvage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393932" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cell salvage for minimising perioperative allogeneic blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27495095" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353044" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17462454" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199817" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Von Willebrand's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540459" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : How I treat the acquired von Willebrand syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28691229" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Desmopressin use for minimising perioperative blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893176" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425225" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Initial Postoperative Hemoglobin Values and Clinical Outcomes in Transfused Patients Undergoing Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32675637" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The Attributable Mortality of Postoperative Bleeding Exceeds the Attributable Mortality of Postoperative Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062700" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : An international consensus statement on the management of postoperative anaemia after major surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21824940" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977360" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A Contemporary Analysis of Phlebotomy and Iatrogenic Anemia Development Throughout Hospitalization in Critically Ill Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25290084" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : From Bad to Worse: Anemia on Admission and Hospital-Acquired Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30084167" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Postoperative anaemia: balancing the risks of anaemia and transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966249" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177268" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Disorders of iron metabolism. Part II: iron deficiency and iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557445" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : From Tolerating Anemia to Treating Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27570088" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28535237" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28198084" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29558233" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30930140" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Intravenous Iron Versus Placebo in the Management of Postoperative Functional Iron Deficiency Anemia in Patients Undergoing Cardiac Valvular Surgery: A Prospective, Single-Blinded, Randomized Controlled Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
